Abstract：MECP2 duplication syndrome (MDS) is a rare pediatric disease and mainly manifests as delayed motor development, language loss or delay, recurrent infection, severe intellectual disability, epilepsy, autistic symptoms, and early infantile hypotonia. In this article, the three children with this disease were all boys. Cases 1 and 2 had delayed motor development, and language loss or delay as initial manifestations, and case 3 had recurrent infection as initial manifestation. Physical examination showed hypotonia and negative pathological signs in each case. Case 1 had tonic-clonic seizures and electroencephalography showed focal seizures, for which he was given oxcarbazepine, levetiracetam, and clonazepam as the antiepileptic treatment to control seizures. Case 3 experienced one absence seizure and three head-nodding seizures with normal electroencephalographic findings during these seizures, and therefore, he was not given antiepileptic treatment. In each case, recurrent infection was improved with the increase in age, but there were no significant improvements in language or intelligence. Array-based comparative genomic hybridization (aCGH) showed MECP2 duplication in X chromosome in each case, and so they were diagnosed with MDS. MDS should be considered for children with delayed development complicated by recurrent infection and epileptic seizures, and early aCGH helps with the diagnosis of this disease.
TANG Dan-Xia,LI Dong-Fang,WU Ruo-Hao et al. MECP2 duplication syndrome: a clinical analysis of three cases and literature review[J]. CJCP, 2017, 19(5): 489-493.
Ramocki MB, Tavyev YJ, Peters SU. The MECP2 duplication syndrome[J]. Am J Med Genet A, 2010, 152A(5):1079-1088.
[2]
Xu X, Xu Q, Zhang Y, et al. A case report of Chinese brothers with inherited MECP2-containing duplication:autism and intellectual disability, but not seizures or respiratory infections[J]. BMC Med Genet, 2012, 13:75.
[3]
Yi Z, Pan H, Li L, et al. Chromosome Xq28 duplication encompassing MECP2:Clinical and molecular analysis of 16 new patients from 10 families in China[J]. Eur J Med Genet, 2016, 59(6-7):347-353.
Lin DS, Chuang TP, Chiang MF, et al. De novo MECP2 duplication derived from paternal germ line result in dysmorphism and developmental delay[J]. Gene, 2014, 533(1):78-85.
[6]
Zhang Q, Zhao Y, Yang Y, et al. MECP2 duplication syndrome in a Chinese family[J]. BMC Med Genet, 2015, 16:112.
[7]
Van Esch H. MECP2 duplication syndrome[M]//Pagon RA, Adam MP, Ardinger HH, et al. GeneReviews®.[Internet]. Seattle (WA):University of Washington, Seattle; 1993-2017.
[8]
Lubs H, Abidi F, Bier JA, et al. XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28[J]. Am J Med Genet, 1999, 85(3):243-248.
[9]
Honda S, Hayashi S, Nakane T, et al. The incidence of hypoplasia of the corpus callosum in patients with dup (X)(q28) involving MECP2 is associated with the location of distal breakpoints[J]. Am J Med Genet A, 2012, 158A(6):1292-1303.
[10]
Lugtenberg D, Kleefstra T, Oudakker AR, et al. Structural variation in Xq28:MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy[J]. Eur J Hum Genet, 2009, 17(4):444-453.
[11]
Van Esch H. MECP2 duplication syndrome[J]. Mol Syndromol, 2012, 2(3-5):128-136.
[12]
Carvalho CM, Zhang F, Liu P, et al. Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching[J]. Hum Mol Genet, 2009, 18(12):2188-2203.
Ausió J, Martínez de Paz A, Esteller M. MeCP2:the long trip from a chromatin protein to neurological disorders[J]. Trends Mol Med, 2014, 20(9):487-498.
[15]
Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription[J]. Science, 2008, 320(5880):1224-1229.
[16]
Na ES, Nelson ED, Kavalali ET, et al. The impact of MeCP2 loss-or gain-of-function on synaptic plasticity[J]. Neuropsychopharmacology, 2013, 38(1):212-219.
[17]
Na ES, Nelson ED, Adachi M, et al. A mouse model for MeCP2 duplication syndrome:MeCP2 overexpression impairs learning and memory and synaptic transmission[J]. J Neurosci, 2012, 32(9):3109-3117.
[18]
Signorini C, De Felice C, Leoncini S, et al. MECP2 duplication syndrome:evidence of enhanced oxidative stress. A omparison with Rett syndrome[J]. PLoS One, 2016, 11(3):e0150101.
[19]
Yang T, Ramocki MB, Neul JL, et al. Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses[J]. Sci Transl Med, 2012, 4(163):163ra158.
[20]
Sztainberg Y, Chen HM, Swann JW, et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides[J]. Nature, 2015, 528(7580):123-126.
[21]
Lim Z, Downs J, Wong K, et al. Expanding the clinical picture of the MECP2 duplication syndrome[J]. Clin Genet, 2017, 91(4):557-563.
[22]
Vignoli A, Borgatti R, Peron A, et al. Electroclinical pattern in MECP2 duplication syndrome:eight new reported cases and review of literature[J]. Epilepsia, 2012, 53(7):1146-1155.
[23]
Ramocki MB, Peters SU, Tavyev YJ, et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome[J]. Ann Neurol, 2009, 66(6):771-782.
